Notfälle
Blutspende
Karriere
Presse
Forschung
Lehre
Patienten
Zuweiser
Übersicht Abstracts für Kongresse 2012
| Nr. | Name des Abstracts | Autoren | Konferenz |
| 1. | Hypoxia-induced alterations of VHL-/VHL+ tumor cells and modulation of angiogenesis by inhibitors | Leisz, Erb, Leich, Seliger | Keystone Snowbird Resort, Utah, USA 16.-21.01.2012 |
| 2. | Hypoxia-induced alterations of renal cell carcinoma and their modulation by tyrosine kinase inhibitors | Leisz, Erb, Leich, Müller, Seliger | AACR 2012, Chicago, USA |
| 3. | Effects of sunitinib treatment on the immune cell populations during long term treatment of renal cell carcinoma patients | Seliger, Giersberg, Staehler | ASCO 2012, Chicago, USA 01.–05.06.2012 |
| 4. | Flipper: First line pazopanib in poor risk patients with metastatic renal cell carcinoma | Staehler, Bergmann, Goebell, Gruenwald, Schenck, Wirth, Teich- mann, Rieder, Seliger | ASCO 2012, Chicago, USA 01.–05.06.2013 |
| 5. | An open-label, multicenter, randomized phase II study: Sequential therapy with bevacizumab, RAD001 (everolimus) and tyrosine kinase inhibitors (TKIs) in metastatic renal cell carcinoma (mRCC) (BERAT study) | Grünwald, Seliger | ASCO 2012, Chicago, USA 01.–05.06.2014 |
| 6. | The regulation of anti-MHC class I antigen processing components associated with absence of tumor suppressive activity and enhanced signal transduction | Steven, Leisz, Bukur, Seliger | PIVAC Meeting 2012, Nottingham, UK 10. – 13.09.2012 |
| 7. | The role of oncogenes, tumor-suppressor genes and signal transduction pathways in the modulation of the MHC class I antigen processing pathway in human tumor cells | Seliger | EU-Grant |
| 8. | Immune suppressive activity mediated by oncogenes and loss of tumor suppressor gene activity | Bukur, Leisz, Steven, Recktenwald, Hiebl, Seliger | SITC Meeting 2012, Washington, USA 24. - 28.10.2012 |
| 9. | Differential effects of the tyrosine kinase inhibitors in T cell growth properties and activity | Stehle, Fahldieck, Kalich, Schulz, Riemann, Seliger | SITC Meeting 2012, Washington, USA 24. - 28.10.2013 |
| 10. | The molecular mechanisms of MHC class I abnormalities in tumors: the role of oncogenes, tumor suppressor genes and beyond | Seliger | Melanoma Bridge 2012, Naples, Italy 02. - 04.12.2012 |
| 11. | Characterization of Hypoxia-regulated alterations in the metabolism and protein expression of renal cell carcinoma | Leisz, Stehle, Erb, Jasinski, Seliger | ISPDC Meeting 2012 Kyoto, Japan 12. – 13.10.2012 |
| 12. | The role of oncogenes, tumor suppressor genes and beyond in MHC class I-mediated immune escape mechanisms | Seliger | Immunotherapy Meeting 2012 New York, USA 01. – 04.10.2012 |
| 13. | Immune escape mechanisms: from tumors, immune cell populations to the microenvironment and beyond | Seliger | ENTIRE Meeting 2012 Belgrad, Serbien 19. – 21.09.2012 |
| 14. | Clinical relevance of miR-mediated regulation of HLA-G expression in renal cell carcinoma | Jasinski, Bukur, Massa, Hartmann, Braun, Huettelmaier, Seliger | Antigen Processing and Presentation in health and disease 2012, Luxemburg 15. – 16.11.2012 |
| 15. | Charakterisierung der Expression und Funktion von Syndekan-2 in humanen Tumoren | Barthel |
